Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + inactivated poliomyelitis vaccine
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **combination vaccine** used to provide immunization against **tetanus, diphtheria, pertussis (whooping cough), and poliomyelitis** in a single injection. This vaccine contains **tetanus toxoid, reduced diphtheria toxoid, acellular pertussis components, and inactivated poliomyelitis virus antigens**. It is mainly used for booster vaccination of children (typically aged 4-6 years) and adults, providing long-lasting protection against these diseases. The immune response is generated by stimulating the body to produce protective antibodies to all included antigens, thereby helping prevent or attenuate the respective diseases if encountered[3][5][7].
- Brand names
- Adacel-PolioBoostrix-Polio
- Other names
- Tdap-IPVTdap-IPV vaccine
02
Targets
Diphtheria toxinPV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + inactivated poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + inactivated poliomyelitis vaccine.